Skip to main content
OpenTrials
Completed

NCT Number: NCT00318721

Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar

A cluster-randomized vector control trial in Bihar, India, and neighboring Nepal, will test the efficacy of long-lasting impregnated bednets (LLINs, Permanets) for reducing visceral leishmaniasis incidence. The intervention unit is the village (400-1000 people). The study is designed to detect a 50% reduction in Leishmania donovani incidence in intervention compared to control clusters over 2 years. 24 clusters (selected as high incidence during previous years) will be randomly allocated to intervention or control. Following health education, and with informed consent, all households in intervention villages will receive free Permanets (from September 2006). Net usage will be monitored and new nets provided if required. Control villages will not be given untreated nets, as - although commonly used in this region - their effectiveness against sandflies has not been proven. Pre-intervention infection status of villagers (>2 yrs) will be evaluated serologically from finger-prick blood (and past/current disease status noted). Incident infections will be recorded by 3-monthly active search for clinical cases, and by annual serological diagnoses to detect subclinical infections. All villagers (>2yrs) will be leishmanin skin tested at the end of the trial for further subclinical infection detection, and sera from a sub-sample will be tested for antibodies to sandfly saliva antigens (a measure of sandfly exposure). All clinical cases will be given free treatment. Free Permanets will be provided to control villages after the trial. Complementary studies involve entomological surveillance by light traps in a sample of houses and social/economic questionnaire surveys. The entomological surveys will test whether community-wide use of LLINs provides any mass effect, which could protect those in the community who fail to use LLIN for any reason.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kala Azar Medical Research Center, Muzaffarpur, Bihar, India

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

(Clusters):

  • at least have seen 1 case per year in each of the last 3 years
  • An average of at least 1% Incidence rate over the period of past 3 years.

Exclusion criteria

(Clusters):

  • Minimum 500 people
  • Maximum 2000 people
  • Distance between clusters 2000 meters (distance between borders)
  • Houses in tola/ward not sprayed (DDT, other) in 2006
  • Accessibility

Treatment and study plan

Long Lasting Impregnated Nets (LLIN)

Device

Distribution of LLIN in selected clusters

Primary outcomes

  1. L. donovani infection

    Time frame: yearly

Secondary outcomes

  1. Kala Azar cases

    Time frame: quarterly

Sponsors and collaborators

Lead sponsor

London School of Hygiene and Tropical Medicine

Other

Collaborators

  • B.P. Koirala Institute of Health Sciences
  • Institute of Medical Sciences of the Banaras Hindu University, India
  • Institute of Tropical Medicine, Belgium
  • International Centre for Diarrhoeal Disease Research, Bangladesh
  • Rajendra Memorial Research Institute of Medical Sciences
  • University Hospital, Geneva

Registry information

Acronym: KALANET

Important dates

Study start
2006
Primary completion
2008
Study completion
2009
First posted
Apr 27, 2006
Registry last updated
Nov 4, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.